2026
台寶生醫（6892）於 2026 年 5 月 15 日召開董事會，通過其美國孫公司 Singulera Therapeutics Inc. 正式向全球頂尖醫療機構美國梅約醫學中心（Mayo Clinic）取得先進 CAR-Treg 技術授權，作為開發新一代細胞治療產品之核心技術。
透過與 Mayo Clinic 的深度結盟，台寶生醫成功擴展了旗下的產品管線與技術深度。
這項指標性合作不僅能藉由 Mayo Clinic 的全球崇高聲譽，全面提升台寶在國際學研機構及一線醫療體系間的戰略合作機會，更為 Singulera 未來在海外的策略聯盟、推進國際臨床試驗，以及次世代技術的進一步授權，奠定了極為關鍵的商業與品牌基礎。
In compliance with EU personal data protection laws, we are committed to protecting and providing you with control over your personal data. By clicking "Accept All", you allow us to place cookies to enhance your experience on this site, help us analyze site performance and usage, and enable us to deliver relevant marketing content. You can manage your cookie settings below. By clicking "Agree" you agree to the current settings. For more information, please visit the Privacy Statement.
This website uses cookies
In compliance with EU personal data protection laws, we are committed to protecting your personal data and providing you with control over it. By clicking "Agree", you allow us to place cookies to improve your experience on this site, help us analyze site performance and usage, and allow us to deliver relevant marketing content.
By clicking "Only necessary" you allow us to place only necessary cookies. The website cannot function without these cookies and you cannot switch them off on your system. These cookies are typically set only in response to an action you perform (i.e. a service request), such as setting privacy preferences, logging in, or filling in a form. You can set your browser to block or prompt you for these cookies, but this may prevent some site features from working.
